[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

China Relapsed Acute Myeloid Leukemia Drug Market Research Report 2018

March 2018 | 113 pages | ID: C0DF900282FEN
QYResearch

US$ 3,400.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global Relapsed Acute Myeloid Leukemia Drug market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

China plays an important role in global market, with market size of xx million USD in 2017 and will be xx million USD in 2025, with a CAGR of xx%.

This report studies the Relapsed Acute Myeloid Leukemia Drug development status and future trend in China, focuses on top players in China, also splits Relapsed Acute Myeloid Leukemia Drug by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.

The major players in China market include
  • 4SC AG
  • AbbVie Inc.
  • Actinium Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arog Pharmaceuticals, Inc.
  • Array BioPharma Inc.
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • BioLineRx, Ltd.
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Calithera Biosciences, Inc.
  • Celgene Corporation
  • Cornerstone Pharmaceuticals, Inc.
  • CTI BioPharma Corp.
Geographically, this report splits the China market into six regions,
  • South China
  • East China
  • Southwest China
  • Northeast China
  • North China
  • Central China
  • Northwest China
On the basis of product, this report displays the sales volume (K Pcs), revenue (Million USD), product price (USD/Pcs), market share and growth rate of each type, primarily split into
  • aNK Program
  • AT-9283
  • BI-836858
  • binimetinib
  • BL-8040
  • Others
On the basis of the end users/application, this report covers
  • Clinic
  • Hospital
  • Others
If you have any special requirements, please let us know and we will offer you the report as you want.
China Relapsed Acute Myeloid Leukemia Drug Market Research Report 2018

1 RELAPSED ACUTE MYELOID LEUKEMIA DRUG OVERVIEW

1.1 Product Overview and Scope of Relapsed Acute Myeloid Leukemia Drug
1.2 Classification of Relapsed Acute Myeloid Leukemia Drug by Product Category
  1.2.1 China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) Comparison by Type (2013-2025)
  1.2.2 China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) Market Share by Type in 2017
  1.2.3 aNK Program
  1.2.4 AT-9283
  1.2.5 BI-836858
  1.2.6 binimetinib
  1.2.7 BL-8040
  1.2.8 Others
1.3 China Relapsed Acute Myeloid Leukemia Drug Market by Application/End Users
  1.3.1 China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Market Share Comparison by Applications (2013-2025)
  1.3.2 Clinic
  1.3.3 Hospital
  1.3.4 Others
1.4 China Relapsed Acute Myeloid Leukemia Drug Market by Region
  1.4.1 China Relapsed Acute Myeloid Leukemia Drug Market Size (Million USD) Comparison by Region (2013-2025)
  1.4.2 South China Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2013-2025)
  1.4.3 East China Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2013-2025)
  1.4.4 Southwest China Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2013-2025)
  1.4.5 Northeast China Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2013-2025)
  1.4.6 North China Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2013-2025)
  1.4.7 Central China Relapsed Acute Myeloid Leukemia Drug Status and Prospect (2013-2025)
1.5 China Market Size (Sales and Revenue) of Relapsed Acute Myeloid Leukemia Drug (2013-2025)
  1.5.1 China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (%)(2013-2025)
  1.5.2 China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (%)(2013-2025)

2 CHINA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET COMPETITION BY PLAYERS/MANUFACTURERS

2.1 China Relapsed Acute Myeloid Leukemia Drug Sales and Market Share of Key Players/Manufacturers (2013-2018)
2.2 China Relapsed Acute Myeloid Leukemia Drug Revenue and Share by Players/Manufacturers (2013-2018)
2.3 China Relapsed Acute Myeloid Leukemia Drug Average Price (USD/Pcs) by Players/Manufacturers (2013-2018)
2.4 China Relapsed Acute Myeloid Leukemia Drug Market Competitive Situation and Trends
  2.4.1 China Relapsed Acute Myeloid Leukemia Drug Market Concentration Rate
  2.4.2 China Relapsed Acute Myeloid Leukemia Drug Market Share of Top 3 and Top 5 Players/Manufacturers
  2.4.3 Mergers & Acquisitions, Expansion in China Market
2.5 China Players/Manufacturers Relapsed Acute Myeloid Leukemia Drug Manufacturing Base Distribution, Sales Area, Product Types

3 CHINA RELAPSED ACUTE MYELOID LEUKEMIA DRUG SALES AND REVENUE BY REGION (2013-2018)

3.1 China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Market Share by Region (2013-2018)
3.2 China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Market Share by Region (2013-2018)
3.3 China Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs) by Regions (2013-2018)

4 CHINA RELAPSED ACUTE MYELOID LEUKEMIA DRUG SALES AND REVENUE BY TYPE/ PRODUCT CATEGORY (2013-2018)

4.1 China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Market Share by Type/ Product Category (2013-2018)
4.2 China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Market Share by Type (2013-2018)
4.3 China Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs) by Type (2013-2018)
4.4 China Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (%) by Type (2013-2018)

5 CHINA RELAPSED ACUTE MYELOID LEUKEMIA DRUG SALES BY APPLICATION (2013-2018)

5.1 China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Market Share by Application (2013-2018)
5.2 China Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (%) by Application (2013-2018)
5.3 Market Drivers and Opportunities

6 CHINA RELAPSED ACUTE MYELOID LEUKEMIA DRUG PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 4SC AG
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
  6.1.4 Main Business/Business Overview
6.2 AbbVie Inc.
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
  6.2.4 Main Business/Business Overview
6.3 Actinium Pharmaceuticals, Inc.
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
  6.3.4 Main Business/Business Overview
6.4 Agios Pharmaceuticals, Inc.
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
  6.4.4 Main Business/Business Overview
6.5 Amgen Inc.
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
  6.5.4 Main Business/Business Overview
6.6 Arog Pharmaceuticals, Inc.
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
  6.6.4 Main Business/Business Overview
6.7 Array BioPharma Inc.
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
  6.7.4 Main Business/Business Overview
6.8 Astellas Pharma Inc.
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
  6.8.4 Main Business/Business Overview
6.9 Astex Pharmaceuticals, Inc.
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
  6.9.4 Main Business/Business Overview
6.10 AstraZeneca Plc
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
  6.10.4 Main Business/Business Overview
6.11 AVEO Pharmaceuticals, Inc.
6.12 BioLineRx, Ltd.
6.13 Boehringer Ingelheim GmbH
6.14 Boston Biomedical, Inc.
6.15 Bristol-Myers Squibb Company
6.16 Calithera Biosciences, Inc.
6.17 Celgene Corporation
6.18 Cornerstone Pharmaceuticals, Inc.
6.19 CTI BioPharma Corp.

7 RELAPSED ACUTE MYELOID LEUKEMIA DRUG MANUFACTURING COST ANALYSIS

7.1 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Relapsed Acute Myeloid Leukemia Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Relapsed Acute Myeloid Leukemia Drug Major Manufacturers in 2017
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 CHINA RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET SIZE (SALES AND REVENUE) FORECAST (2018-2025)

11.1 China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD) Forecast (2018-2025)
11.2 China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) Forecast by Type (2018-2025)
11.3 China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) Forecast by Application (2018-2025)
11.4 China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) Forecast by Region (2018-2025)

12 RESEARCH FINDINGS AND CONCLUSION

13 METHODOLOGY AND DATA SOURCE

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES

Figure Global and China Market Size (Million USD) Comparison (2013-2025)
Table Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Revenue (Million USD) Market Split by Product Type
Table Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) by Application (2013-2025)
Figure Product Picture of Relapsed Acute Myeloid Leukemia Drug
Table China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (%) Comparison by Types (Product Category) (2013-2025)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Types in 2017
Figure aNK Program Product Picture
Figure AT-9283 Product Picture
Figure BI-836858 Product Picture
Figure binimetinib Product Picture
Figure BL-8040 Product Picture
Figure Others Product Picture
Figure China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) Comparison by Application (2013-2025)
Figure China Sales Market Share (%) of Relapsed Acute Myeloid Leukemia Drug by Application in 2017
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Others Examples
Table Key Downstream Customer in Others
Figure South China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure East China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Northeast China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure North China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Central China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (%)(2013-2025)
Figure China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (%)(2013-2025)
Table China Relapsed Acute Myeloid Leukemia Drug Sales of Key Players/Manufacturers (2013-2018)
Table China Relapsed Acute Myeloid Leukemia Drug Sales Share (%) by Players/Manufacturers (2013-2018)
Figure 2017 China Relapsed Acute Myeloid Leukemia Drug Sales Share (%) by Players/Manufacturers
Figure 2017 China Relapsed Acute Myeloid Leukemia Drug Sales Share (%) by Players/Manufacturers
Table China Relapsed Acute Myeloid Leukemia Drug Revenue by Players/Manufacturers (2013-2018)
Table China Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) by Players/Manufacturers (2013-2018)
Figure 2017 China Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) by Players/Manufacturers
Figure 2017 China Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) by Players/Manufacturers
Table China Market Relapsed Acute Myeloid Leukemia Drug Average Price of Key Players/Manufacturers (2013-2018)
Figure China Market Relapsed Acute Myeloid Leukemia Drug Average Price of Key Players/Manufacturers in 2017
Figure China Relapsed Acute Myeloid Leukemia Drug Market Share of Top 3 Players/Manufacturers
Figure China Relapsed Acute Myeloid Leukemia Drug Market Share of Top 5 Players/Manufacturers
Table China Players/Manufacturers Relapsed Acute Myeloid Leukemia Drug Manufacturing Base Distribution and Sales Area
Table China Players/Manufacturers Relapsed Acute Myeloid Leukemia Drug Product Category
Table China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) by Regions (2013-2018)
Table China Relapsed Acute Myeloid Leukemia Drug Sales Share (%) by Regions (2013-2018)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Share (%) by Regions (2013-2018)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Market Share (%) by Regions in 2017
Table China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Market Share by Regions (2013-2018)
Table China Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) by Regions (2013-2018)
Figure China Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) by Regions (2013-2018)
Figure China Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) by Regions in 2017
Table China Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs) by Regions (2013-2018)
Table China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) by Type (2013-2018)
Table China Relapsed Acute Myeloid Leukemia Drug Sales Share (%) by Type (2013-2018)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Share (%) by Type (2013-2018)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Market Share (%) by Type in 2017
Table China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Market Share by Type (2013-2018)
Table China Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) by Type (2013-2018)
Figure Revenue Market Share of Relapsed Acute Myeloid Leukemia Drug by Type (2013-2018)
Figure Revenue Market Share of Relapsed Acute Myeloid Leukemia Drug by Type in 2017
Table China Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs) by Types (2013-2018)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (%) by Type (2013-2018)
Table China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) by Applications (2013-2018)
Table China Relapsed Acute Myeloid Leukemia Drug Sales Market Share (%) by Applications (2013-2018)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Market Share (%) by Application (2013-2018)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Market Share (%) by Application in 2017
Table China Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (%) by Application (2013-2018)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate (%) by Application (2013-2018)
Table 4SC AG Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (%)(2013-2018)
Figure 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales Market Share (%) in China (2013-2018)
Figure 4SC AG Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) in China (2013-2018)
Table AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (%)(2013-2018)
Figure AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share (%) in China (2013-2018)
Figure AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) in China (2013-2018)
Table Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (%)(2013-2018)
Figure Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share (%) in China (2013-2018)
Figure Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) in China (2013-2018)
Table Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (%)(2013-2018)
Figure Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share (%) in China (2013-2018)
Figure Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) in China (2013-2018)
Table Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (%)(2013-2018)
Figure Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share (%) in China (2013-2018)
Figure Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) in China (2013-2018)
Table Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (%)(2013-2018)
Figure Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share (%) in China (2013-2018)
Figure Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) in China (2013-2018)
Table Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (%)(2013-2018)
Figure Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share (%) in China (2013-2018)
Figure Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) in China (2013-2018)
Table Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (%)(2013-2018)
Figure Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share (%) in China (2013-2018)
Figure Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) in China (2013-2018)
Table Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (%)(2013-2018)
Figure Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Market Share (%) in China (2013-2018)
Figure Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) in China (2013-2018)
Table AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
Figure AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (%)(2013-2018)
Figure AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales Market Share (%) in China (2013-2018)
Figure AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (%) in China (2013-2018)
Table AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Relapsed Acute Myeloid Leukemia Drug
Figure Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug
Figure Relapsed Acute Myeloid Leukemia Drug Industrial Chain Analysis
Table Raw Materials Sources of Relapsed Acute Myeloid Leukemia Drug Major Players/Manufacturers in 2017
Table Major Buyers of Relapsed Acute Myeloid Leukemia Drug
Table Distributors/Traders List
Figure China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
Figure China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure China Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs) Trend Forecast (2018-2025)
Table China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) Forecast by Type (2018-2025)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) Forecast by Type (2018-2025)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share Forecast by Type in 2025
Table China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) Forecast by Application (2018-2025)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share Forecast by Application (2018-2025)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share Forecast by Application in 2025
Table China Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) Forecast by Regions (2018-2025)
Table China Relapsed Acute Myeloid Leukemia Drug Sales Volume Share Forecast by Regions (2018-2025)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Volume Share Forecast by Regions (2018-2025)
Figure China Relapsed Acute Myeloid Leukemia Drug Sales Volume Share Forecast by Regions in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories